Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	* recurring covid-19 patients * subjects with any unstable conditions, a history of significant hypersensitivity, or known allergy to components of the investigational agent * receipt of convalescent covid-19 plasma, sars-cov-2 mab treatment, sars-cov-2 vaccine, or other investigational treatments prior to study entry	* recurring covid-19 patients * subjects with any unstable conditions, a history of significant hypersensitivity, or known allergy to components of the investigational agent * receipt of convalescent covid-19 plasma, sars-cov-2 mab treatment, sars-cov-2 vaccine, or other investigational treatments prior to study entry
March 9, 2021, 12:31 a.m.	usa	- recurring covid-19 patients - subjects with any unstable conditions, a history of significant hypersensitivity, or known allergy to components of the investigational agent - receipt of convalescent covid-19 plasma, sars-cov-2 mab treatment, sars-cov-2 vaccine, or other investigational treatments prior to study entry	- recurring covid-19 patients - subjects with any unstable conditions, a history of significant hypersensitivity, or known allergy to components of the investigational agent - receipt of convalescent covid-19 plasma, sars-cov-2 mab treatment, sars-cov-2 vaccine, or other investigational treatments prior to study entry